HLA typing Apr 4, 2022 European Commission Approves Immunocore's T-Cell Receptor Therapy Kimmtrak in Uveal Melanoma Jan 26, 2022 FDA Approves Immunocore's T-Cell Receptor Therapy Kimmtrak for Uveal Melanoma Patients Jun 5, 2021 Engineered TCR Therapy Demonstrates Durable Responses in Rare Sarcomas Apr 10, 2021 Immunocore's Tebentafusp Prolongs Survival in Uveal Melanoma Patients, AACR Study Shows Premium Nov 16, 2020 Somatic Mutations in Lung Cancer Patients With HLA Supertype B44 Influence Immunotherapy Response Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer